GRAIL/The Galleri Test

The Galleri® multi-cancer early detection test is the first product from GRAIL, a healthcare company whose mission is to detect cancer early when it can be cured. Using the power of next-generation DNA sequencing, population-scale clinical studies, and state-of-the-art computer and data science to overcome one of medicine’s greatest challenges, GRAIL is focused on saving lives and improving health by pioneering new technologies for early cancer detection. The Galleri® test complements guideline-recommended screenings, and can detect a cancer signal across more than 50 types of cancer through a routine blood draw. When cancer is detected, the Galleri test can predict the cancer signal origin. For more information visit Galleri.com.